Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Search
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Living with GPP
Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
Digital Transformation Within Our Global IT
Technology is at the heart of our strategy.
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Meet the Partnering Team Video 2023
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
cat feline diabetes medication treatment eu approval
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Improving Access to Stroke Care
Angels Initiative named Best Practice example by the Access to Medicine Index
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Vaccine prevent calf diarrhea
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved